ABBV vs. AMGN, GILD, MRNA, ABT, BMY, JNJ, LLY, MRK, PFE, and ZTS
Should you be buying AbbVie stock or one of its competitors? The main competitors of AbbVie include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Abbott Laboratories (ABT), Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), Pfizer (PFE), and Zoetis (ZTS). These companies are all part of the "medical" sector.
AbbVie vs. Its Competitors
AbbVie (NYSE:ABBV) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.
70.2% of AbbVie shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.3% of AbbVie shares are owned by insiders. Comparatively, 0.8% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
AbbVie has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500.
In the previous week, AbbVie had 41 more articles in the media than Amgen. MarketBeat recorded 99 mentions for AbbVie and 58 mentions for Amgen. Amgen's average media sentiment score of 1.13 beat AbbVie's score of 0.94 indicating that Amgen is being referred to more favorably in the news media.
AbbVie pays an annual dividend of $6.56 per share and has a dividend yield of 3.2%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.3%. AbbVie pays out 312.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie has increased its dividend for 53 consecutive years and Amgen has increased its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and lower payout ratio.
AbbVie currently has a consensus price target of $214.95, indicating a potential upside of 3.39%. Amgen has a consensus price target of $304.43, indicating a potential upside of 6.59%. Given Amgen's higher probable upside, analysts plainly believe Amgen is more favorable than AbbVie.
AbbVie has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.
Amgen has a net margin of 18.96% compared to AbbVie's net margin of 6.45%. AbbVie's return on equity of 699.66% beat Amgen's return on equity.
Summary
AbbVie beats Amgen on 12 of the 20 factors compared between the two stocks.
Get AbbVie News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ABBV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NYSE:ABBV) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access